449 related articles for article (PubMed ID: 28222336)
121. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
122. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.
Mangaonkar AA; Lasho TL; Finke CM; Gangat N; Al-Kali A; Elliott MA; Begna KH; Alkhateeb H; Wolanskyj-Spinner AP; Hanson CA; Ketterling RP; Hogan WJ; Pardanani A; Litzow MR; Tefferi A; Patnaik MM
Blood Cancer J; 2018 Feb; 8(2):18. PubMed ID: 29434284
[No Abstract] [Full Text] [Related]
123. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
124. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
[TBL] [Abstract][Full Text] [Related]
125. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Lachowiez CA; Loghavi S; Furudate K; Montalban-Bravo G; Maiti A; Kadia T; Daver N; Borthakur G; Pemmaraju N; Sasaki K; Alvarado Y; Yilmaz M; Short NJ; Chien K; Ohanian M; Pierce S; Patel KP; Jabbour E; Ravandi F; Kantarjian HM; Garcia-Manero G; Takahashi K; Konopleva MY; DiNardo CD
Blood Adv; 2021 Apr; 5(8):2173-2183. PubMed ID: 33885753
[TBL] [Abstract][Full Text] [Related]
126. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
[TBL] [Abstract][Full Text] [Related]
127. [Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome].
Zhao WS; Zhang YT; Jiang QL; Liu QF; Dai M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1977-1984. PubMed ID: 33283729
[TBL] [Abstract][Full Text] [Related]
128. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
129. Myelodysplastic syndromes with ring sideroblasts.
Bruzzese A; Vigna E; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Barbato A; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M
Hematol Oncol; 2023 Oct; 41(4):612-620. PubMed ID: 36794650
[TBL] [Abstract][Full Text] [Related]
130. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
[TBL] [Abstract][Full Text] [Related]
131. Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up.
Matsuda K; Ishida F; Ito T; Nakazawa H; Miura S; Taira C; Sueki A; Kobayashi Y; Honda T
Leuk Res; 2012 Nov; 36(11):1393-7. PubMed ID: 22902051
[TBL] [Abstract][Full Text] [Related]
132. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
[TBL] [Abstract][Full Text] [Related]
133. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Chesnais V; Kosmider O; Damm F; Itzykson R; Bernard OA; Solary E; Fontenay M
Oncotarget; 2012 Nov; 3(11):1284-93. PubMed ID: 23327988
[TBL] [Abstract][Full Text] [Related]
134. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Trsova I; Hrustincova A; Krejcik Z; Kundrat D; Holoubek A; Staflova K; Janstova L; Vanikova S; Szikszai K; Klema J; Rysavy P; Belickova M; Kaisrlikova M; Vesela J; Cermak J; Jonasova A; Dostal J; Fric J; Musil J; Dostalova Merkerova M
Mol Oncol; 2023 Dec; 17(12):2565-2583. PubMed ID: 37408496
[TBL] [Abstract][Full Text] [Related]
135. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
[TBL] [Abstract][Full Text] [Related]
136. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
[TBL] [Abstract][Full Text] [Related]
137. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
138. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
139. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
140. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]